デフォルト表紙
市場調査レポート
商品コード
1414663

膣炎治療薬の世界市場レポート 2024年

Vaginitis Therapeutics Global Market Report 2024

出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.36円
膣炎治療薬の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2~10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

膣炎治療薬の市場規模は近年急速に拡大しています。2023年の37億4,000万米ドルから2024年には41億2,000万米ドルに、CAGR10.1%で拡大します。過去の期間における成長は、膣感染症の有病率の高さ、女性の健康に対する意識の高まり、ライフスタイルや衛生習慣の変化、抗生物質耐性に対する懸念、医薬品研究開発の進展と関連しています。

膣炎治療薬市場の成長が期待される背景には、性感染症(STD)の有病率の増加があります。性感染症(STDs)は、感染者と非感染者の性的接触によって感染する感染症で、膣炎を引き起こし、膣の炎症や痛みを引き起こします。膣炎治療薬は、女性のSTDによる膣炎に伴う症状を緩和する上で重要な役割を担っており、膣炎治療薬の普及に貢献しています。例えば、2023年4月現在、米国疾病管理予防センターは、米国におけるSTD症例の増加を報告しており、2020年から2021年にかけて250万人を突破しました。梅毒患者は、2020年の133,954人から2021年には176,713人へと32%も増加しました。その結果、STDの蔓延が深刻化し、膣炎治療薬市場の成長を促進すると予想されます。

2023年の膣炎治療薬世界市場で最大の地域は北米でした。膣炎治療薬市場レポートの対象地域は、アジア太平洋,西欧,東欧,北米,南米,中東,アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年~2023年
  • 世界の市場規模予測と成長、2023年~2028年、2033年

第6章 市場セグメンテーション

  • 世界の膣炎治療薬市場、薬剤タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ニトロイミダゾール化合物
  • リンコサミド系抗生物質
  • トリアゾール
  • イミダゾール
  • 世界の膣炎治療薬市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 経口
  • 皮膚
  • 経膣
  • 世界の膣炎治療薬市場、適応症別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 細菌性膣炎
  • トリコモナス症
  • 外陰膣カンジダ症
  • その他のタイプ
  • 世界の膣炎治療薬市場、エンドユーザー別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 外来手術センター
  • 専門の婦人科センター
  • クリニック

第7章 地域および国の分析

  • 世界の膣炎治療薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の膣炎治療薬市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 膣炎治療薬市場の競合情勢
  • 膣炎治療薬市場の企業プロファイル
    • Pfizer Inc.
    • Merck &Co Inc.
    • Novartis AG
    • Bayer AG
    • Lupin Pharmaceuticals Inc.

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

目次
Product Code: r12173

“Vaginitis Therapeutics Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vaginitis therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vaginitis therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The vaginitis therapeutics market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Drug Type: Nitroimidazole Compound; Lincosamide Antibiotics; Triazoles; Imidazoles
  • 2) By Route Of Administration: Oral; Cutaneous; Vaginal
  • 3) By Indication Type: Bacterial Vaginosis; Trichomoniasis; Vulvovaginal Candidiasis; Other Types
  • 3) By End Users: Hospitals; Ambulatory Surgical Centers; Specialized Gynecology Centers; Clinics
  • Companies Mentioned: Pfizer Inc.; Merck & Co Inc.; Novartis AG; Bayer AG; Lupin Pharmaceuticals Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Vaginitis therapeutics involves the utilization of drugs, such as antifungal agents, antibiotics, and hormonal medications, for the treatment of vaginal infections. These drugs effectively alleviate symptoms such as itching, discharge, and pain.

The primary drug types for vaginitis therapeutics include nitroimidazole compounds, lincosamide antibiotics, triazoles, and imidazoles. Nitroimidazoles encompass a group of antimicrobial medications effective against parasites, mycobacteria, and anaerobic gram-positive and gram-negative bacteria. These drugs can be administered orally, topically, or vaginally, and they are indicated for conditions such as bacterial vaginosis, trichomoniasis, vulvovaginal candidiasis, and others. End users for these therapeutics include hospitals, ambulatory surgical centers, specialized gynecology centers, and clinics.

The vaginitis therapeutics market research report is one of a series of new reports from The Business Research Company that provides vaginitis therapeutics market statistics, including vaginitis therapeutics industry global market size, regional shares, competitors with a vaginitis therapeutics market share, detailed vaginitis therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the vaginitis therapeutics industry. This vaginitis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vaginitis therapeutics market size has grown rapidly in recent years. It will grow from $3.74 billion in 2023 to $4.12 billion in 2024 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historical period is associated with a high prevalence of vaginal infections, increased awareness of women's health, changes in lifestyles and hygiene practices, concerns about antibiotic resistance, and advancements in pharmaceutical research and development.

The vaginitis therapeutics market size is expected to see rapid growth in the next few years. It will grow to $6.03 billion in 2028 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historical period is associated with a high prevalence of vaginal infections, increased awareness of women's health, changes in lifestyles and hygiene practices, concerns about antibiotic resistance, and advancements in pharmaceutical research and development.

The anticipated growth in the vaginitis therapeutics market is driven by the increasing prevalence of sexually transmitted diseases (STDs). Sexually transmitted diseases (STDs) are infections transmitted through sexual contact between infected and uninfected individuals, causing vaginitis, which leads to vaginal inflammation and pain. Vaginitis therapeutics play a crucial role in alleviating symptoms associated with STD-induced vaginitis among women, contributing to the widespread use of vaginitis drugs. For example, as of April 2023, the Center for Disease Control and Prevention reported a rise in STD cases in the USA, surpassing 2.5 million between 2020 and 2021. Syphilis cases saw a notable 32% increase from 133,954 in 2020 to 176,713 in 2021. Consequently, the escalating prevalence of STDs is expected to drive growth in the vaginitis therapeutics market.

Changing fertility trends are also poised to boost the vaginitis therapeutics market in the forthcoming years. Fertility, denoting the inherent capacity of an organism, person, or group to have children, is a critical aspect of human biology. Vaginitis therapeutics may enhance fertility by addressing underlying infections or illnesses that could impact reproductive health. Notably, as of June 2023, the Vital Statistics Rapid Release report from the Centers for Disease Control and Prevention highlighted a marginal decrease of less than 1% in the overall fertility rate from 2021, settling at 56.1 births per 1,000 women aged 15 to 44. Thus, changing fertility trends serve as a driving force behind the vaginitis therapeutics market.

Product innovation stands out as a prominent trend gaining traction in the vaginitis therapeutics market. Leading companies in this market are dedicated to developing inventive solutions to fortify their market presence. For example, Duchesnay Inc., a Canada-based pharmaceutical company specializing in women's health, introduced Vablys, the pioneering prescription antiseptic and anti-infective treatment tailored for bacterial vaginosis in women under 55 years of age. With multiple modes of action and anti-infective properties against various pathogens, the treatment involves the insertion of one tablet into the vagina at bedtime for six consecutive days.

Major players in the vaginitis therapeutics market prioritize obtaining approvals for groundbreaking products, as exemplified by the U.S. Food and Drug Administration's (FDA) approval of SOLOSEC (secnidazole) for trichomoniasis treatment. SOLOSEC is an antibacterial medication designed to address bacterial vaginosis (BV) and trichomoniasis. Lupin Pharmaceuticals, Inc., a US-based pharmaceutical company, received FDA approval for the expanded use of SOLOSEC in adult trichomoniasis therapy. This authorization positions SOLOSEC as the sole single-dose oral prescription antibacterial medication approved for managing both BV and trichomoniasis, catering to the diverse needs of patients, including those 12 years of age and older.

In October 2021, BioNTech, a Germany-based biotechnology company, acquired PhagoMed, an Austria-based biotechnology company specializing in developing a new class of antibacterial drugs and treatments for recurrent bacterial vaginosis. This strategic acquisition aligns with BioNTech's goal of enhancing its infectious disease portfolio capabilities, reinforcing its commitment to advancing innovative solutions in the vaginitis therapeutics market.

Major companies operating in the vaginitis therapeutics market report are Pfizer Inc., Merck & Co Inc., Novartis AG, Bayer AG, Lupin Pharmaceuticals Inc., Symbiomix Therapeutics Inc., Mission Pharmacal Company, Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals Inc., Lumavita AG, Abbott Laboratories Ltd., GlaxoSmithKline plc, Sanofi SA, Bristol-Myers-Squibb Co, Eli Lilly and Co, TherapeuticsMD Inc., Scynexis Inc., Sebela Pharmaceuticals Inc., Dare Bioscience Inc., Hologic Inc., Mylan N.V., Viamet Pharmaceuticals Inc., Matinas BioPharma Holdings Inc., Cidara Therapeutics Inc., Imprimis Pharmaceuticals Inc., Innovus Pharmaceuticals Inc., Evofem Biosciences Inc., Mycovia Pharmaceuticals, Perrigo Company plc, Mithra Pharmaceuticals, Ferring Pharmaceuticals, AstraZeneca plc, Biocon Limited, Pacira Pharmaceuticals Inc., The Medicines Company

North America was the largest region in the global vaginitis therapeutics market in 2023. The regions covered in the vaginitis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the vaginitis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The vaginitis therapeutics market includes revenues earned by entities by nonhormonal therapy, and antioxidant therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Vaginitis Therapeutics Market Characteristics

3. Vaginitis Therapeutics Market Trends And Strategies

4. Vaginitis Therapeutics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Vaginitis Therapeutics Market Size and Growth

  • 5.1. Global Vaginitis Therapeutics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Vaginitis Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Vaginitis Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Vaginitis Therapeutics Market Segmentation

  • 6.1. Global Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Nitroimidazole Compound
  • Lincosamide Antibiotics
  • Triazoles
  • Imidazoles
  • 6.2. Global Vaginitis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Cutaneous
  • Vaginal
  • 6.3. Global Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Bacterial Vaginosis
  • Trichomoniasis
  • Vulvovaginal Candidiasis
  • Other Types
  • 6.4. Global Vaginitis Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialized Gynecology Centers
  • Clinics

7. Vaginitis Therapeutics Market Regional And Country Analysis

  • 7.1. Global Vaginitis Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Vaginitis Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Vaginitis Therapeutics Market

  • 8.1. Asia-Pacific Vaginitis Therapeutics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Vaginitis Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Vaginitis Therapeutics Market

  • 9.1. China Vaginitis Therapeutics Market Overview
  • 9.2. China Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Vaginitis Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Vaginitis Therapeutics Market

  • 10.1. India Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Vaginitis Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Vaginitis Therapeutics Market

  • 11.1. Japan Vaginitis Therapeutics Market Overview
  • 11.2. Japan Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Vaginitis Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Vaginitis Therapeutics Market

  • 12.1. Australia Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Vaginitis Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Vaginitis Therapeutics Market

  • 13.1. Indonesia Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Vaginitis Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Vaginitis Therapeutics Market

  • 14.1. South Korea Vaginitis Therapeutics Market Overview
  • 14.2. South Korea Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Vaginitis Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Vaginitis Therapeutics Market

  • 15.1. Western Europe Vaginitis Therapeutics Market Overview
  • 15.2. Western Europe Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Vaginitis Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Vaginitis Therapeutics Market

  • 16.1. UK Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Vaginitis Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Vaginitis Therapeutics Market

  • 17.1. Germany Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Vaginitis Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Vaginitis Therapeutics Market

  • 18.1. France Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Vaginitis Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Vaginitis Therapeutics Market

  • 19.1. Italy Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Vaginitis Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Vaginitis Therapeutics Market

  • 20.1. Spain Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Vaginitis Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Vaginitis Therapeutics Market

  • 21.1. Eastern Europe Vaginitis Therapeutics Market Overview
  • 21.2. Eastern Europe Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Vaginitis Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Vaginitis Therapeutics Market

  • 22.1. Russia Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Vaginitis Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Vaginitis Therapeutics Market

  • 23.1. North America Vaginitis Therapeutics Market Overview
  • 23.2. North America Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Vaginitis Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Vaginitis Therapeutics Market

  • 24.1. USA Vaginitis Therapeutics Market Overview
  • 24.2. USA Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Vaginitis Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Vaginitis Therapeutics Market

  • 25.1. Canada Vaginitis Therapeutics Market Overview
  • 25.2. Canada Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Vaginitis Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Vaginitis Therapeutics Market

  • 26.1. South America Vaginitis Therapeutics Market Overview
  • 26.2. South America Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Vaginitis Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Vaginitis Therapeutics Market

  • 27.1. Brazil Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Vaginitis Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Vaginitis Therapeutics Market

  • 28.1. Middle East Vaginitis Therapeutics Market Overview
  • 28.2. Middle East Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Vaginitis Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Vaginitis Therapeutics Market

  • 29.1. Africa Vaginitis Therapeutics Market Overview
  • 29.2. Africa Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Vaginitis Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Vaginitis Therapeutics Market Competitive Landscape And Company Profiles

  • 30.1. Vaginitis Therapeutics Market Competitive Landscape
  • 30.2. Vaginitis Therapeutics Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Merck & Co Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Novartis AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Bayer AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Lupin Pharmaceuticals Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Vaginitis Therapeutics Market Competitive Benchmarking

32. Global Vaginitis Therapeutics Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Vaginitis Therapeutics Market

34. Vaginitis Therapeutics Market Future Outlook and Potential Analysis

  • 34.1 Vaginitis Therapeutics Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Vaginitis Therapeutics Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Vaginitis Therapeutics Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer